SOURCE: EmpowHER

EmpowHER

June 14, 2010 19:38 ET

Interview Advisory: Leading Women's Health Advocate to Testify to FDA Panel About Breakthrough Medication for Women's Sexual Disorders

Michelle King Robson of EmpowHER to Provide Personal Story of Need for New Treatments for Women

SCOTTSDALE, AZ--(Marketwire - June 14, 2010) -

WHAT: Michelle King Robson http://www.empowher.com/michelle, one of the nation's leading women's health and wellness advocates and Founder, Chairperson and CEO of EmpowHER, a health media company for women, will share her personal testimony with a panel of the Food and Drug Administration on June 18, 2010 about women's sexual health, and a condition called Hyposexual Desire Disorder (HSDD), also known as low libido.
   
  "I am speaking about my personal story following my hysterectomy and its adverse affects on my own sexual health. And, I'm bringing with me the voice of millions of women who come to EmpowHER.com every year to talk about their own health and wellness. Many of these women share their personal health struggles with each other, and with caregivers and medical experts on the site because they feel like they are 'not the same' person they once were," King Robson said.
   
  The FDA panel is expected to make a final decision about the approval of a medication called Flibanserin -- the so-called "pink pill or female Viagra." King Robson cites the fact that Viagra has been around for more than a decade and women's sexual enhancement medications have languished in the approval process for years. "It's time for women's sexual disorders to be addressed by the medical community. This medication could pave the way for many new therapies," she said, noting that EmpowHER has set up a special resource section for women and the media, specifically dedicated to this issue, which can be found at www.empowher.com/pinkpill.
   
  King Robson and EmpowHER have not been personally or commercially involved with Flibanserin or its manufacturer, drug maker Boehringer Ingelheim. Nonetheless, King Robson maintains, "This is a step in the right direction. Flibanserin won't be the silver bullet for all women, but that is not the point. The point is that women's sexual health is, by virtue of this FDA hearing and the preponderance of this drug, being given its due. Whatever other drugs, treatments or procedures follow Flibanserin into the market will only further advance and improve women's sexual health. I have long maintained, if men had hysterectomies, or experienced menopause or hormonal issues; this problem would have been solved decades ago. It's time for women to be heard. And, I'm honored to have an opportunity to be a mouthpiece for tens of millions of women who suffer in silence with this dysfunction."
   
WHEN: King Robson will testify to the FDA panel in Washington, D.C. on June 18, 2010.
   
WHO: Michelle King Robson is one of the nation's leading women's health advocates. In 2006, Michelle's advocacy work pushed her to lead a petition and mail-in campaign against a major pharmaceutical company whom she believes was pushing a "one-size-fits-all" drug and trying to halt the production of compounded medicine to treat hormonal issues -- this was later recorded by the FDA as the second largest campaign of its kind in history. Her efforts have helped pave the way for increased awareness and action regarding a number of women's health disorders, including menopause, sexual dysfunction, breast cancer and many others. Following her own personal medical nightmare after undergoing an unnecessary hysterectomy, King Robson began advocating for other women and eventually founded a health media company for women whose website, www.EmpowHER.com, was launched 18 months ago. Today, EmpowHER is the 5th largest website in its category, reaching almost a million women per month.
   
WHY: King Robson's testimony is a formal part of the final approval process for medications presented to the FDA. Besides leading physicians and scientists who have studied the medication, the panel seeks voices from those whose lives have been directly affected by the unmet need for such a class of medications.
   
BOOKINGS: We can arrange for an interview with King Robson, who has been interviewed by leading health care newsmakers including NPR, PBS, NBC News, Health Radio The Wall Street Journal, More Magazine, The Huffington Post and many others.

Contact Information

  • CONTACT:
    Jay Geer
    Miller Geer Arizmendez
    562-467-2020
    Email Contact